ArticleFrontiers in immunology2021
Astragaloside IV Alleviates the Experimental DSS-Induced Colitis by Remodeling Macrophage Polarization Through STAT Signaling.
Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 94 citations in OpenAlex.
- Preclinical studies of natural flavonoids in inflammatory bowel disease based on macrophages: a systematic review with meta-analysis and network pharmacology.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- The gut microbiota-tryptophan metabolism-immune axis in inflammatory bowel disease: Mechanisms and therapeutic prospects.Human vaccines & immunotherapeutics · 2026Review
- Astragaloside IV suppresses triple-negative breast cancer cell migration and invasion by targeting BCAT1-mediated branched-chain amino acid metabolism.Oncology letters · 2026Article
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
- Astragaloside IV Exhibited Antidiabetic Effects by Improving Glucose Metabolism, Repairing Damaged Gut Barrier and Regulating Intestinal Microbiota.Phytotherapy research : PTR · 2026Article
- Astragaloside IV Alleviates DSS-Induced Ulcerative Colitis by Modulating Host-Gut Tryptophan Metabolism.Foods (Basel, Switzerland) · 2026Article
- Astragaloside IV fromAntioxidants (Basel, Switzerland) · 2026Article
- Ethanol extract of Astragali Radix inhibits M1 macrophage polarization to alleviate ulcerative colitis by promoting Lactobacillus reuteri-produced indole-3-carboxaldehyde and formononetin.Chinese medicine · 2026Article
- Astragaloside IV ameliorates DSS-induced intestinal epithelial barrier dysfunction associated with modulation of tight junction proteins and MLCK/p-MLC and MyD88/TRAF6 signaling pathways.Frontiers in pharmacology · 2026Article
- Wenyang Decoction Ameliorates DSS-Induced Ulcerative Colitis by Regulating Macrophage Polarization and the PI3K/AKT/mTOR/HIF-1α Signaling Pathway.Mediators of inflammation · 2026Article
- The role ofFrontiers in immunology · 2026Review
- Modulation of gut microbiota and metabolic profiles by Astragaloside IV in a chronic enteritis model.Frontiers in cellular and infection microbiology · 2026Article
- H7F ameliorates DSS-induced colitis through restoration of intestinal barrier function and inhibition of IL-17/NF-κb signaling.Frontiers in pharmacology · 2026Article
- Astragaloside IV inhibits the progression of hypertensive heart disease via the RXRA/PPARG/SIRT3 axis.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Procyanidin-B1-EnrichedAnimals : an open access journal from MDPI · 2025Article
- Octanoic Acid-Rich Enteral Nutrition Regulates Intestinal M1/M2 Macrophage Polarization via the PPARγ/STAT-1/STAT-6 Pathway to Alleviate Inflammatory Bowel Disease.Food science & nutrition · 2025Article
- Astragaloside IV regulates macrophage polarization via the TLR4/NF-κB/STAT3 pathway to inhibit the malignant phenotype of renal clear cell carcinoma.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Astragaloside IV Alleviates Ulcerative Colitis Progression by Inhibiting WDR5-Mediated ENO1 H3K4me3 Modification.The Kaohsiung journal of medical sciences · 2025Article
- Integrated bioinformatics and network pharmacology to identify and validate macrophage polarization related hub genes in the treatment of osteoarthritis with Astragalus membranaceus.Journal of orthopaedic surgery and research · 2025Article
- Mechanism of Astragaloside IV in Treatment of Renal Tubulointerstitial Fibrosis.Chinese journal of integrative medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD) is characterized by chronic and relapsing intestinal inflammation, which currently lacks safe and effective medicine. Some previous studies indicated that Astragaloside IV (AS-IV), a natural saponin extracted from the traditional Chinese medicine herb
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.